摘要
目的:观察吉非替尼(Iressa)单药治疗非小细胞肺癌(NSCLC)患者的近远期疗效及毒副反应。方法:48例均经病理组织学确诊的NSCLC患者,口服吉非替尼单药250mg,1次/d,2个月后评价疗效及评价后4周疗效确认,停用吉非替尼的标准为疾病进展或不良反应不能耐受。结果:48例患者均可评价疗效,CR4例,PR16例,总有效率(RR)为41.6%,SD16例,疾病控制率(DCR)为75.0%,PD12例,性别、病理类型、吸烟史和年龄等因素都与近期有效率(RR)相关。有效患者的中位缓解时间为12个月(95%CI为5.6～16.6个月),中位生存期为12.5个月(95%CI为8.6～14.2个月),中位肿瘤进展时间为8.4个月(95%CI为4.1～10.2个月),1年生存率为42.6%。生活质量明显改善。与药物相关的不良反应依次为皮疹、腹泻、恶心、关节痛和肝功能异常。结论:吉非替尼治疗疗效明确。毒副反应较轻,耐受性较好,可以明显改善患者生存质量,作为NSCLC的治疗药物值得推广。
OBJECTIVE： To observe the efficacy and drug related toxicities of gefitinib in the treatment of patients with advanced non-small cell lung cancer. METHODS： Forty eight patients with non-small cell lung cancer confirmed by pathology were studied. All of them were orally administrated with gefinitib 250 mg/d until the disease progression or intolerable toxicities. The effect was evaluated after 2 months, and 4 week after the evcluation the effect was affirmed. RESULTS： All the 48 patients could be evaluated with 4 cases of CR and 16 cases of PR. RR was 41. 6%. There were 16 cases of SD. DCR was 75. 0%. There were 12 cases of PD. Sex, pathology,history of smoking and age were related to RR respectively. The middle relieval time was 12 months （95%CI：5.6-16.6 months）. The middlesurviv altime was 12.5 months（95%CI：8.6-14.2 months）. The middle time of progression was 8. 4 months（95%CI：4. 1-10. 2 months）. The 1-year survival rate was 42. 6%. The most corn mon drug related adverse events were rash, diarrhea, nausea and vomit and most of which were endurable. CONCLUSION： Gefitinib seems to be safe and effective in the treatment of advanced adenocarcinoma, and female, non-smoker and adenocarcinoma are related to high effect.
出处
《中华肿瘤防治杂志》
CAS
2009年第23期1881-1883,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
吉非替尼
靶向治疗
癌
非小细胞肺/药物疗法
gefitinib
target therapy
cancer
carcinoma non-small cell lung/drug therapy
